Drug Trial Radar · NCT07732634
Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Nov 2029
Study completion Nov 2031
Sponsor
- Lead sponsor
- University of Illinois ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Coordination Pharmaceuticals, Inc.
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab). The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.
Conditions
- Head and Neck Cancer
- Head Cancer
- Neck Cancer
Interventions
RiMO-301Drug
RiMO-301 will be dosed on Day 0 prior to radiotherapy. The injection point will be as closed to half of the tumor depth as possible.
PembrolizumabDrug
Pembrolizumab will be administered at 200 mg once every 3 weeks (Q3W) with the first dose on Day 0 +/- 1 day. Pembrolizumab will be given for a total of two cycles prior to surgery.
RadiationRadiation
Hypofractionated radiation will will be given within 1 day after RiMO-301 injection and will continue over a period of 5-15 days. Participants will be receive 5 fractions of radiation with a dose of 4-5 Gray per fraction.
Surgical resectionProcedure
Surgical resection of the tumor will occur following neoadjuvant therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by major pathologic response (i.e., percentage of participants whose tumors shrink).Time frame: At surgical resection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Illinois at Chicago
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.